By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Immunization have been published. According to news reporting originating in Chapel Hill, North Carolina, by NewsRx journalists, research stated, "Achievement of potent immunoresponses against self/tumor antigens and effective therapeutic outcome against advanced tumors remain major challenges in cancer immunotherapy. The specificity and efficiency of two nanoparticle-based delivery systems, lipid-calcium-phosphate (LCP) nanoparticle (NP) and liposome-protamine-hyaluronic acid (LPH) NP, provide us an opportunity to address both challenges."
The news reporters obtained a quote from the research from the University of North Carolina, "A mannose-modified LCP NP delivered both tumor antigen (Trp 2 peptide) and adjuvant (CpG oligonucleotide) to the dendritic cells and elicited a potent, systemic immune response regardless of the existence or the stage of tumors in the host. This vaccine was less effective, however, against later stage B16F10 melanoma in a subcutaneous syngeneic model. Mechanistic follow-up studies suggest that elevated levels of immune-suppressive cytokines within the tumor microenvironment, such as TGF-beta, might be responsible. We strategically augment the efficacy of LCP vaccine on an advanced tumor by silencing TGF-beta in tumor cells. The delivery of siRNA using LPH NP resulted in about 50% knockdown of TGF-beta in the late stage tumor microenvironment. TGF-beta down-regulation boosted the vaccine efficacy and inhibited tumor growth by 52% compared with vaccine treatment alone, as a result of increased levels of tumor infiltrating CD8+ T cells and decreased level of regulatory T cells."
According to the news reporters, the research concluded: "Combination of systemic induction of antigen-specific immune response with LCP vaccine and targeted modification of tumor microenvironment with LPH NP offers a flexible and powerful platform for both mechanism study and immunotherapeutic strategy development."
For more information on this research see: Nanoparticle-Delivered Transforming Growth Factor-beta siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment. ACS Nano, 2014;8(4):3636-3645. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)
Our news correspondents report that additional information may be obtained by contacting Z.H. Xu, University of North Carolina, Eshelman Sch Pharm, Center Nanotechnol Drug Delivery, Div Mol Pharmaceut, Chapel Hill, NC 27599, United States. Additional authors for this research include Y.H. Wang, L. Zhang and L. Huang (see also Immunization).
Keywords for this news article include: Vaccines, Cytokines, Chapel Hill, Vaccination, Immunization, United States, Immunotherapy, North Carolina, Immunomodulation, Biological Products, North and Central America, TGF-beta Superfamily Proteins, Transforming Growth Factor beta, Intercellular Signaling Peptides and Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC